688298.SH
Zhejiang Orient Gene Biotech Co., Ltd.
SSE · Healthcare · Medical - Specialties · CN
CNY 18.71
−3.71%Sep 10, 2026, 04:11 UTC
Zhejiang Orient Gene Biotech stated that its quantum dot flow fluorescence equipment and reagents have obtained multiple domestic and international certificates, have been gradually industrialized, and have entered domestic and international markets.
Source:Sep 10, 2026, 04:11 UTC
At its 2026 interim online results briefing held on September 10, Zhejiang Orient Gene Biotech stated that it has developed high-quality Ebola antigen detection and nucleic acid detection reagents and has laid out detection reagents for other vector-borne diseases.
Source:Sep 3, 2026, 11:47 UTC
OriGene Biotech and its wholly-owned subsidiary Shanghai Wanzijian Bio recently obtained multiple medical device registration certificates in China and overseas, covering syphilis antibody detection, HPV nucleic acid typing, and thyroid-stimulating hormone detection products.
Source:Aug 28, 2026, 08:28 UTC
OriGene Biotech reported a net loss of 222 million yuan for the first half of 2026, compared with a loss of 163 million yuan in the same period of 2025.
Source: